Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevurogant (BI 730357) in active psoriatic arthritis
NCT04680676Phase 2Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of bevurogant in psoriatic arthritis (PsA), sponsored by Boehringer Ingelheim. Planned start May 2022; status: withdrawn.
02
Drugs
bevurogant
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04680676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680676.